Vexxa Lifesciences


VE Pharma
Concise Prescribing Info
Locally advanced or metastatic non-small cell lung cancer (NSCLC) w/ activating mutations of EGFR-TK in adult.
Dosage/Direction for Use
May be taken with or without food: Tab may be dispersed in ½ glass of non-carbonated water. No other liqd should be used. Drop the tab in water & w/o crushing it, stir until dispersed (approx 20 min). Drink the liqd immediately. Rinse the glass w/ another ½ glass of water & drink. Dispersed liqd may also be administered via a nasogastric tube. Take at about the same time each day.
Special Precautions
Avoid false -ve or +ve EGFR determinations. Discontinue if interstitial lung disease or ulcerative keratitis occurs. GI perforation. Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. Avoid concomitant use w/ CYP3A4 inducers (eg, phenytoin, carbamazepine, rifampicin, barbiturates or herbal prep containing St. John's wort). Hepatoxicity & liver impairment. Childn & adolescent <18 yr.
Adverse Reactions
Anorexia; diarrhea, vomiting, nausea, stomatitis; elevation in alanine aminotransferase; skin reactions mainly pustular rash; fissures, asthenia. Conjunctivitis, blepharitis, dry eye; hemorrhage (eg, epistaxis & hematuria); interstitial lung disease; dehydration, dry mouth; elevation in aspartate aminotransferase & total bilirubin; nail disorder, alopecia; asymptomatic lab elevations in blood creatinine, proteinuria, cystitis; pyrexia.
Drug Interactions
Increase metabolism & decrease plasma conc w/ rifampicin or phenytoin. INR elevations &/or bleeding events w/ warfarin. Decrease metabolism & increase plasma conc w/ ketoconazole & itraconazole. May reduce plasma conc w/ ranitidine & cimetidine. Reduced efficacy w/ phenytoin, carbamazepine, rifampicin, barbiturates, or herbal prep containing St. John's wort. Reduced bioavailability & plasma conc w/ PPIs. H2 antagonist & antacids. May exacerbate the neutropenic effect of vinorelbine.
ATC Classification
L01EB01 - gefitinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Gafvex FC tab 250 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in